

Improved Early Detection of Ovarian Cancer with Dual Biomarker Algorithm

A new study, published in the peer-reviewed journal "Cancers", shows that using AroCell TK 210 ELISA in combination with traditional biomarkers CA 125 and HE4 can significantly improve sensitivity and outperform the ROMA index in the early-stage detection of ovarian cancer.

In this study, the aim was to explore the diagnostic value of AroCell TK 210 ELISA in combination with CA 125, and HE4 for the early-stage detection of ovarian cancer. Published in the "Cancers" journal, and titled "A Dual Biomarker TK1 Protein and CA125 or HE4-Based Algorithm as a Better Diagnostic Tool than ROMA Index in Early Detection of Ovarian Cancer".

In collaboration with the University Medical Center in Ljubljana, Slovenia, serum samples were collected from 134 patients, both benign and malignant, and used AroCell TK 210 ELISA to determine TK1 protein levels, along with CA 125, HE4, and ROMA Index. The results reveal that the dual biomarker combination of TK 210 + CA 125 or TK 210 + HE4 has higher sensitivity for detecting early-stage ovarian cancer and significantly outperforms the ROMA index.

These findings suggest that using TK1 protein determinations in conjunction with CA 125 or HE4 could prove to be a valuable tool for healthcare providers to aid in the diagnosis and treatment of ovarian cancer.

The link to the article: <https://www.mdpi.com/2072-6694/15/5/1593>.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Press Release
06 March 2023 12:10:00 CET



Attachments

[Improved Early Detection of Ovarian Cancer with Dual Biomarker Algorithm](#)